Clinical Trial Update: The Trial of SHR6508 in Secondary Hyperparathyroidism [Phase 3]

View source ↗

Summary

A Phase 3 trial of SHR6508 for secondary hyperparathyroidism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• SHR6508 (SHR6508)

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Secondary Hyperparathyroidism | Phase 3 | Status: COMPLETED